Instil Bio | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.13 12:15
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -2.01, beating the estimate of USD -2.355.

EBIT: As of FY2025 Q3, the actual value is USD -14.33 M.

Segment Revenue

Instil Bio, Inc. operates in a single segment focused on the research and development of novel therapies, particularly the development of AXN-2510/IMM2510.

Operational Metrics

  • Net Loss: The company reported a net loss of $13.6 million for the three months ended September 30, 2025, compared to a net loss of $23.0 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $63.2 million, compared to $62.2 million in 2024.
  • Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $15.0 million, down from $23.6 million in 2024. For the nine months ended September 30, 2025, operating expenses were $69.0 million, compared to $61.7 million in 2024.
  • Research and Development: R&D expenses increased to $9.1 million for the three months ended September 30, 2025, from $0.6 million in 2024. For the nine months ended September 30, 2025, R&D expenses were $21.2 million, up from $10.7 million in 2024.
  • General and Administrative: G&A expenses decreased to $5.9 million for the three months ended September 30, 2025, from $10.7 million in 2024. For the nine months ended September 30, 2025, G&A expenses were $21.2 million, down from $33.8 million in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities was $29.5 million for the nine months ended September 30, 2025, compared to $45.1 million in 2024.
  • Investing Cash Flow: Net cash provided by investing activities was $17.7 million for the nine months ended September 30, 2025, compared to $41.0 million in 2024.
  • Financing Cash Flow: Net cash provided by financing activities was $7.3 million for the nine months ended September 30, 2025, compared to $0.2 million in 2024.

Unique Metrics

  • Assets Held for Sale: As of September 30, 2025, the company had $112.1 million in assets related to the Tarzana facility classified as held for sale.

Future Outlook and Strategy

  • Core Business Focus: Instil Bio, Inc. is focused on advancing the development of its lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting PD-L1 and VEGF in solid tumor cancers. The company aims to in-license or acquire additional novel therapeutic candidates.
  • Non-Core Business: The company has listed its Tarzana facility for sale, which is currently leased to AstraZeneca Pharmaceuticals LP. The sale of this facility could potentially extend the company’s expected cash runway beyond 2026.

Priority

The company emphasizes its strategic focus on the development and commercialization of AXN-2510/IMM2510, with ongoing clinical trials and collaborations to support its growth and market expansion.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.